Company intelligence / Profile preview

Nimbus Concepts

Cambridge/Boston, MA, United Statesventureradar.com ↗

Ownership: Private
Development stage: Other

Overview

Nimbus has advanced multiple small molecule programs into clinical development using its computational platform. Notable achievements include positive Phase IIb data in plaque psoriasis for NDI‑034858 before its sale to Takeda, as well as preclinical milestones in oncology and metabolic disease. Its pipeline includes a WRN inhibitor for MSI-H tumors and AMPK activators in collaboration with Eli Lilly.

Therapeutic areas: ImmunologyMetabolic DisordersOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Eli Lilly & Company (collaboration on AMPK activators)Gilead Sciences (acquired ACC program/Nimbus Apollo)Takeda Pharmaceuticals (acquired TYK2 inhibitor/Nimbus Lakshmi)

Beyond the preview

Go deeper on Nimbus Concepts.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nimbus Concepts.

Explore the full profile